Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document foreign issuer current reports, oncology program updates, financing transactions, governance changes, and liquidity-related disclosures. The company furnishes Form 6-K reports and references Form 20-F reporting status, with exhibits covering financial results, clinical updates for vebreltinib, and corporate developments affecting ongoing operations.
The filing record also covers material agreements, related-party convertible note financing, PIPE share issuance, resale registration obligations, board and committee appointments, proxy materials, and risk disclosures tied to cash resources, collaboration payments, Nasdaq listing compliance, and the company’s capital structure as a Cayman Islands issuer with Class A ordinary shares and warrants.
Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.
Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.
Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.
Apollomics Inc. reports major governance and leadership changes following a September 4, 2025 board meeting. The board appointed Yi-An Chu and Chen-Huan (Jack) Jan as new independent directors, bringing the board to seven members, five of whom are independent. The board also reconstituted key committees: the audit committee now includes Po-Jen Hsueh, Hsien-Shu Tsai (chairman), and Yi-An Chu; the compensation committee includes Moses Chen (chairman), Hsien-Shu Tsai, and Yi-An Chu; and the nominating and corporate governance committee includes Moses Chen, Po-Jen Hsueh, and Chen-Huan Jan (chairman).
The board named Hung-Wen (Howard) Chen as Chairman and Chief Executive Officer, appointed Yi-Kuei Chen as Chief Operating Officer, and Peter Lin as Chief Financial Officer, each bringing extensive experience in biotechnology, technology, finance, and private equity. The filing also corrects prior disclosure by stating that, following issuance of PIPE shares, Howard Chen and his affiliates beneficially own approximately 42% of Apollomics’ outstanding Class A ordinary shares, while Maxpro Investment Co., Ltd. and its affiliates beneficially own approximately 4.9%.
Apollomics Inc. filed a Form 6-K reporting biographical details for Po-Jen Hsueh and attaching an exhibit reference to a PIPE Subscription Agreement dated September 2, 2025. The filing states Mr. Hsueh has over 15 years of experience in operations, finance, and business development in the biopharmaceutical sector, including roles as COO of ACT Genomics and prior work at TaiGen Biotechnology where he participated in multiple financing rounds that together raised $114 million USD. The registrant also notes it will furnish omitted schedules and exhibits to the SEC upon request. The report is signed by Howard Chen, Chairman, dated September 3, 2025.
Apollomics Inc. reported that, due to its cash position, it is terminating all U.S. employees, including its Chief Executive Officer, Dr. Guo-Liang Yu, and Chief Financial Officer, Dr. Matthew Plunkett, effective August 29, 2025. This indicates a severe reduction of U.S. operations and leadership.
The company also stated that it expects to discontinue all activities related to its SPARTA clinical trial as soon as possible, signaling a shutdown of this development program. In addition, Apollomics has called an Extraordinary General Meeting of Shareholders for September 4, 2025, to seek shareholder approval for winding up the company, which would effectively bring its corporate existence to an end if approved.